2014 Press Releases

Webcast ImageWebcast
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Live)
08/15/17 at 12:45 p.m. ET
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Tuesday, August 15, 2017 12:45 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/02/14Audentes Therapeutics Raises $42.5 Million In Series B Financing
Deerfield, Sofinnova, and Venrock Join Existing Investors to Propel Leading Gene Therapy Company Through Significant Clinical and Corporate Development MilestonesSAN FRANCISCO, CA – December 2, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the closing of a $42.5 million Series B financing. Deerfield Management led the financing with participation fro... 
Printer Friendly Version
11/20/14Audentes Therapeutics To Present At The Piper Jaffray Healthcare Conference
SAN FRANCISCO, CA – November 20, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, December 2, 2014 at 12:30pm Eastern.About Audentes Therapeutics, Inc.Audentes is a biotechno... 
Printer Friendly Version
10/01/14Audentes Therapeutics Announces Continued Expansion Of Senior Management Team
John T. Gray, Ph.D., Brings Leading Gene Therapy Research and Manufacturing Expertise to CompanySAN FRANCISCO, CA – October 1, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, has announced the continued expansion of its leadership team, including the appointment of John T. Gray, PhD., as Vice President, Research and Development.  Dr. Gray brings more than 20 year... 
Printer Friendly Version
09/24/14Audentes Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
SAN FRANCISCO, CA – September 24, 2014 – Audentes Therapeutics, Inc., a private biotechnology company dedicated to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York City on October 1, 2014.About Audentes Therapeutics, Inc.Audentes is a biotechnology company committed to t... 
Printer Friendly Version
05/19/14Audentes Therapeutics Announces Six Abstracts To Be Presented At The American Society Of Gene And Cell Therapy Meeting May 21-24, 2014
Data to be presented demonstrate continued encouraging results from preclinical studies of AT001 for the treatment of X-Linked Myotubular MyopathySAN FRANCISCO – May 19, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the presentation of results from ongoing preclinical studies of AT001 (AAV-MTM1), Audentes’ novel therapeutic in development for th... 
Printer Friendly Version
03/04/14Audentes Therapeutics Announces Significant Additions To Leadership Team
Dr. Suyash Prasad joins as Senior Vice President and Chief Medical OfficerSAN FRANCISCO, CA – March 4, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development and commercialization of innovative treatments for rare diseases using gene therapy technology, has announced the expansion of its leadership team, including the appointment of Suyash Prasad, M.D. as Senior Vice President and Chief Medical Officer.  Dr. Prasad is the latest addition to a managemen... 
Printer Friendly Version
02/05/14Audentes Therapeutics And Genethon Announce Agreement To Develop Treatment For Severe Genetic Disease X-linked Myotubular Myopathy
Promising preclinical data recently published in Science Translational MedicineSAN FRANCISCO, CA – February 5, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non-profit organization dedicated to the research and development of biotherapies for orphan genetic diseases, announce that they have entered into an agreement to develop AT001 for the treatment of X-Linked Myotubular Myopathy (XLMT... 
Printer Friendly Version